The webinar is free of charge. No preliminary registration required.
***A few minutes of Q&A will be allocated after each presentation. The audience is invited to ask questions at any time using the “chat feature” in the session room. The webinar chairs will ask questions from this selection during the Q&A.
There have been many recent advances in stroke care, and the need for us to provide high-quality care for people with stroke is as critical now as ever. We are sure you will find these sessions interesting and exciting during this difficult time where our work, personal, and social lives are so disrupted.
Get a glimpse of the upcoming ESO-WSO Conference by attending our webinar on Wednesday, 13 May at 13:00 pm CET.
ABOUT THIS WEBINAR
We are delighted to present you with five of the highest-rated research works which are part of our scientific programme
AGENDA
- Welcome and opening remarks from the ESO and WSO Presidents and the Webinar Chairs (3min)
- Trial 1: Efficacy of Fluoxetine: A Randomized Controlled Trial in Stroke (Effects) Assoc. Prof. Erik Lundström (Sweden) Department of Neuroscience, Neurology, Uppsala University, Akademiska Sjukhuset, Uppsala, Sweden
- Trial 2: Assessment of Fluoxetine in Stroke Recovery (Affinity): Results of a Double-blind, Placebo-controlled, Randomised Trial Prof. Graeme Hankey (Australia) Department of Neurology, Medical School, Faculty of Health and Medical Sciences, The University of Western Australia
- Trial 3: A Randomized Trial of Direct Endovascular Thrombectomy Versus Thrombectomy Preceded by Intravenous Alteplase in Acute Ischemic Stroke Prof. Jianmin Liu (China) Changhai Hospital in Shanghai, Department of Neurosurgery, Cerebrovascular Center, China
- Trial 4: The Basilar Artery International Collaboration Study (Basics): A Randomized Controlled Trial of Endovascular Therapy in Basilar Artery Occlusion Dr. Wouter Schonewille (Netherlands) Department of Neurology, St. Antonius Hospital, Nieuwegein, The Netherlands
- Trial 5: Ascot Trial: The Effect of Randomisation to Atorvastatin or Placebo, and Amlodipine-based or Beta-blocker-based Regime on 20-year Incidence of Stroke or Dementia Dr. William Whiteley (UK) Senior Lecturer, CCBS, University of Edinburgh, Honorary Consultant Neurologist, NHS Lothian, Senior Clinical Fellow, NDPH, University of Oxford
- Closing remarks
Link to webinar can be found on the ESO WSO 2020 Conference website.
